Cadila Healthcare on Thursday announced that the Drug Controller General of India has approved its New Drug Application for Saioglitazar for the treatment of Non-Cirrhotic Non-Alcoholic Steato Hepatitis (NASH) in India.
NASH is a progressive disease of the liver, which starts with fat accumulation in the liver known as Non-Alcohoiic Fatty Liver Disease (NAFLD). This condition could progress to cirrhosis and liver failure. Shareholders will closely monitor further progress.